

Lorenzo Giovanni Mantovani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9032377/publications.pdf>

Version: 2024-02-01

196
papers

8,121
citations

50170

46
h-index

56606

83
g-index

200
all docs

200
docs citations

200
times ranked

9969
citing authors

#	ARTICLE	IF	CITATIONS
1	Adherence to Antihypertensive Medications and Cardiovascular Morbidity Among Newly Diagnosed Hypertensive Patients. <i>Circulation</i> , 2009, 120, 1598-1605.	1.6	524
2	A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 700-710.	1.9	390
3	Risk Profiles and Antithrombotic Treatment of Patients Newly Diagnosed with Atrial Fibrillation at Risk of Stroke: Perspectives from the International, Observational, Prospective GARFIELD Registry. <i>PLoS ONE</i> , 2013, 8, e63479.	1.1	375
4	Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. <i>Blood</i> , 2003, 102, 2358-2363.	0.6	351
5	Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. <i>European Heart Journal</i> , 2016, 37, 2882-2889.	1.0	222
6	Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study. <i>Lancet Haematology</i> , 2016, 3, e12-e21.	2.2	215
7	Anti-Inhibitor Coagulant Complex Prophylaxis in Hemophilia with Inhibitors. <i>New England Journal of Medicine</i> , 2011, 365, 1684-1692.	13.9	209
8	Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. <i>Heart</i> , 2017, 103, 307-314.	1.2	205
9	International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). <i>American Heart Journal</i> , 2012, 163, 13-19.e1.	1.2	195
10	European principles of haemophilia care. <i>Haemophilia</i> , 2008, 14, 361-374.	1.0	191
11	Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. <i>Journal of Hypertension</i> , 2005, 23, 2093-2100.	0.3	163
12	Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors. <i>Haemophilia</i> , 2006, 12, 154-162.	1.0	146
13	Replacement therapy for invasive procedures in patients with haemophilia: literature review, European survey and recommendations. <i>Haemophilia</i> , 2009, 15, 639-658.	1.0	143
14	Italian Population-Based Values of EQ-5D Health States. <i>Value in Health</i> , 2013, 16, 814-822.	0.1	122
15	Prevention of pneumococcal diseases in the post-seven valent vaccine era: A European perspective. <i>BMC Infectious Diseases</i> , 2012, 12, 207.	1.3	121
16	Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry. <i>PLoS ONE</i> , 2016, 11, e0164076.	1.1	118
17	The Economic Burden of Inappropriate Drug Prescribing, Lack of Adherence and Compliance, Adverse Drug Events in Older People. <i>Drug Safety</i> , 2012, 35, 73-87.	1.4	113
18	Comparing the performance of the standard EQ-5D 3L with the new version EQ-5D 5L in patients with chronic hepatic diseases. <i>Quality of Life Research</i> , 2013, 22, 1707-1716.	1.5	108

#	ARTICLE	IF	CITATIONS
19	Costs, quality of life, treatment satisfaction and compliance in patients with β^2 -thalassemia major undergoing iron chelation therapy: the ITHACA study. <i>Current Medical Research and Opinion</i> , 2008, 24, 1905-1917.	0.9	101
20	Detection and Awareness of Moderate to Advanced CKD by Primary Care Practitioners: A Cross-sectional Study From Italy. <i>American Journal of Kidney Diseases</i> , 2008, 52, 444-453.	2.1	98
21	Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors. <i>Haemophilia</i> , 2006, 12, 363-371.	1.0	94
22	Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. <i>BMJ Open</i> , 2017, 7, e017157.	0.8	92
23	Mortality in Patients With Atrial Fibrillation Receiving Nonrecommended Doses of Direct Oral Anticoagulants. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1425-1436.	1.2	88
24	Health technology assessment in interventional electrophysiology and device therapy: a position paper of the European Heart Rhythm Association. <i>European Heart Journal</i> , 2013, 34, 1869-1874.	1.0	85
25	Guidelines for Economic Evaluations in Italy: Recommendations from The Italian Group of Pharmacoeconomic Studies. <i>Drug Information Journal</i> , 2001, 35, 189-201.	0.5	84
26	Treatment with ACE inhibitors or ARBs and risk of severe/lethal COVID-19: a meta-analysis. <i>Heart</i> , 2020, 106, 1519-1524.	1.2	83
27	The Clinical and Economic Impact of Exacerbations of Chronic Obstructive Pulmonary Disease: A Cohort of Hospitalized Patients. <i>PLoS ONE</i> , 2014, 9, e101228.	1.1	79
28	Cost-Effectiveness and Cost-Utility Analysis of Spinal Cord Stimulation in Patients With Failed Back Surgery Syndrome: Results From the PRECISE Study. <i>Neuromodulation</i> , 2015, 18, 266-276.	0.4	77
29	Characteristics and Management of Patients with Venous Thromboembolism: The GARFIELD-VTE Registry. <i>Thrombosis and Haemostasis</i> , 2019, 119, 319-327.	1.8	76
30	A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment. <i>Thrombosis and Haemostasis</i> , 2014, 111, 94-102.	1.8	74
31	Does Sex Affect Anticoagulant Use for Stroke Prevention in Nonvalvular Atrial Fibrillation?. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, S12-20.	0.9	74
32	A Proposal For Italian Guidelines in Pharmacoeconomics. <i>Pharmacoeconomics</i> , 1995, 7, 1-6.	1.7	71
33	Predictors of severe or lethal COVID-19, including Angiotensin Converting Enzyme inhibitors and Angiotensin II Receptor Blockers, in a sample of infected Italian citizens. <i>PLoS ONE</i> , 2020, 15, e0235248.	1.1	71
34	Should prophylaxis be used in adolescent and adult patients with severe haemophilia? An European survey of practice and outcome data. <i>Haemophilia</i> , 2007, 13, 473-479.	1.0	68
35	The Role of European Healthcare Databases for Post-Marketing Drug Effectiveness, Safety and Value Evaluation: Where Does Italy Stand?. <i>Drug Safety</i> , 2019, 42, 347-363.	1.4	65
36	SARS-CoV-2 pandemic: An overview. <i>Advances in Biological Regulation</i> , 2020, 77, 100736.	1.4	65

#	ARTICLE	IF	CITATIONS
37	Differences between patients', physicians' and pharmacists' preferences for treatment products in haemophilia: a discrete choice experiment. <i>Haemophilia</i> , 2005, 11, 589-597.	1.0	60
38	Early Risks of Death, Stroke/Systemic Embolism, and Major Bleeding in Patients With Newly Diagnosed Atrial Fibrillation. <i>Circulation</i> , 2019, 139, 787-798.	1.6	60
39	Health-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the ProFEIBA study. <i>Haemophilia</i> , 2013, 19, 736-743.	1.0	59
40	Major complications have an impact on total annual medical cost of diabetes. <i>Journal of Diabetes and Its Complications</i> , 2006, 20, 163-169.	1.2	55
41	Systematic literature review on economic implications and pharmacoeconomic issues of rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, S72-84.	0.4	55
42	Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 267-277.	1.0	54
43	Management of acute haemarthrosis in haemophilia A without inhibitors: literature review, European survey and recommendations. <i>Haemophilia</i> , 2011, 17, 383-392.	1.0	52
44	An Economic Evaluation of Cetuximab Combined with Radiotherapy for Patients with Locally Advanced Head and Neck Cancer in Belgium, France, Italy, Switzerland, and the United Kingdom. <i>Value in Health</i> , 2008, 11, 791-799.	0.1	51
45	Device therapy and hospital reimbursement practices across European countries: a heterogeneous scenario. <i>Europace</i> , 2011, 13, ii59-ii65.	0.7	50
46	Cost-Effectiveness and Budget Impact of Emicizumab Prophylaxis in Haemophilia A Patients with Inhibitors. <i>Thrombosis and Haemostasis</i> , 2020, 120, 216-228.	1.8	48
47	Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors. <i>Haemophilia</i> , 2007, 13, 38-45.	1.0	47
48	A national survey of the management of atrial fibrillation with antithrombotic drugs in Italian primary care. <i>Thrombosis and Haemostasis</i> , 2010, 103, 968-975.	1.8	46
49	Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: barriers to and strategies for optimal implementation. <i>Europace</i> , 2015, 17, 1007-1017.	0.7	46
50	Global Anticoagulant Registry in the Field – Venous Thromboembolism (GARFIELD-VTE). <i>Thrombosis and Haemostasis</i> , 2016, 116, 1172-1179.	1.8	46
51	Haemophilia Care in Europe: the ESCHQoL study. <i>Haemophilia</i> , 2012, 18, 729-737.	1.0	45
52	Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF. <i>American Heart Journal</i> , 2019, 213, 35-46.	1.2	45
53	Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD-AF Registry. <i>Journal of the American Heart Association</i> , 2019, 8, e010510.	1.6	44
54	Cost-benefit analysis of supplemented very low-protein diet versus dialysis in elderly CKD5 patients. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 907-913.	0.4	41

#	ARTICLE	IF	CITATIONS
55	Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: A Systematic Literature Review. <i>Pharmacoeconomics</i> , 2018, 36, 567-589.	1.7	39
56	The societal burden of chronic liver diseases: results from the COME study. <i>BMJ Open Gastroenterology</i> , 2015, 2, e000025.	1.1	38
57	Comparison of detailed and succinct cohort modelling approaches in a multi-regional evaluation of cervical cancer vaccination. <i>Vaccine</i> , 2008, 26, F16-F28.	1.7	37
58	Immune tolerance induction in patients with haemophilia a and inhibitors: effectiveness and cost analysis in an European Cohort (The <sc>ITER</sc> Study). <i>Haemophilia</i> , 2016, 22, 96-102.	1.0	37
59	The socioeconomic burden of patients affected by hemophilia with inhibitors. <i>European Journal of Haematology</i> , 2018, 101, 435-456.	1.1	37
60	Cost and quality of life in patients with severe chronic hand eczema refractory to standard therapy with topical potent corticosteroids. <i>Contact Dermatitis</i> , 2014, 70, 158-168.	0.8	34
61	Isolated Distal Deep Vein Thrombosis: Perspectives from the GARFIELD-VTE Registry. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1675-1685.	1.8	34
62	Trends in cardiovascular diseases burden and vascular risk factors in Italy: The Global Burden of Disease study 1990â€“2017. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 385-396.	0.8	34
63	Leadership in Public Health: Opportunities for Young Generations Within Scientific Associations and the Experience of the “Academy of Young Leaders”. <i>Frontiers in Public Health</i> , 2019, 7, 378.	1.3	33
64	Predictive value of venous thromboembolism (<sc>VTE</sc>)â€“<sc>BLEED</sc> to predict major bleeding and other adverse events in a practiceâ€“based cohort of patients with <sc>VTE</sc>: results of the <sc>XALIA</sc> study. <i>British Journal of Haematology</i> , 2018, 183, 457-465.	1.2	32
65	Patient preferences and willingness to pay for different options of anticoagulant therapy. <i>Internal and Emergency Medicine</i> , 2013, 8, 237-243.	1.0	31
66	The economic burden of chronic obstructive pulmonary disease in the elderly. <i>Current Opinion in Pulmonary Medicine</i> , 2011, 17, S35-S41.	1.2	30
67	Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELDâ€“VTE patients. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1694-1706.	1.9	30
68	Upper Extremity DVT versus Lower Extremity DVT: Perspectives from the GARFIELD-VTE Registry. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1365-1372.	1.8	28
69	Assessment of Outcomes Among Patients With Venous Thromboembolism With and Without Chronic Kidney Disease. <i>JAMA Network Open</i> , 2020, 3, e2022886.	2.8	28
70	Patientsâ€™, physiciansâ€™, and pharmacistsâ€™ preferences towards coagulation factor concentrates to treat haemophilia with inhibitors: results from the COHIBA Study. <i>Haemophilia</i> , 2009, 15, 473-486.	1.0	27
71	XALIA: rationale and design of a non-interventional study of rivaroxaban compared with standard therapy for initial and long-term anticoagulation in deep vein thrombosis. <i>Thrombosis Journal</i> , 2014, 12, 16.	0.9	27
72	Epidemiologic and Economic Burden Attributable to First Spinal Fusion Surgery. <i>Spine</i> , 2017, 42, 1398-1404.	1.0	27

#	ARTICLE	IF	CITATIONS
73	Setting dialysis start at 6.0 ml/min/1.73 m ² eGFR—a study on safety, quality of life and economic impact. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 3434-3440.	0.4	26
74	Economic evaluation in cardiology. <i>Europace</i> , 2011, 13, ii3-ii8.	0.7	26
75	Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation. <i>JAMA Cardiology</i> , 2019, 4, 526.	3.0	26
76	Recommendations for postmarketing surveillance studies in haemophilia and other bleeding disorders. <i>Haemophilia</i> , 2005, 11, 353-359.	1.0	24
77	Recommendations for reporting economic evaluations of haemophilia prophylaxis: a nominal groups consensus statement on behalf of the Economics Expert Working Group of The International Prophylaxis Study Group. <i>Haemophilia</i> , 2007, 14, 071115150757005-???	1.0	24
78	Role of healthcare databases and registries for surveillance of orphan drugs in the real-world setting: the Italian case study. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 497-509.	1.0	24
79	Burden of Diabetes Mellitus Estimated with a Longitudinal Population-Based Study Using Administrative Databases. <i>PLoS ONE</i> , 2014, 9, e113741.	1.1	24
80	Provoked versus unprovoked venous thromboembolism: Findings from GARFIELD-VTE. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, 326-341.	1.0	23
81	Health technology assessment: what is it? Current status and perspectives in the field of electrophysiology. <i>Europace</i> , 2011, 13, ii49-ii53.	0.7	22
82	Comparative effectiveness of oral anticoagulants in venous thromboembolism: GARFIELD-VTE. <i>Thrombosis Research</i> , 2020, 191, 103-112.	0.8	22
83	Efficiency measures of emergency departments: an Italian systematic literature review. <i>BMJ Open Quality</i> , 2021, 10, e001058.	0.4	22
84	The social burden and quality of life of patients with haemophilia in Italy. <i>Blood Transfusion</i> , 2014, 12 Suppl 3, s567-75.	0.3	22
85	Cost-effectiveness analysis of pharmacokinetic-driven prophylaxis vs. standard prophylaxis in patients with severe haemophilia A. <i>Blood Coagulation and Fibrinolysis</i> , 2017, 28, 425-430.	0.5	21
86	Burden of acute myocardial infarction. <i>International Journal of Cardiology</i> , 2011, 150, 111-112.	0.8	20
87	Meta-analysis on incidence of inhibitors in patients with haemophilia A treated with recombinant factor VIII products. <i>Blood Coagulation and Fibrinolysis</i> , 2017, 28, 627-637.	0.5	20
88	Cost-Utility Analysis of Bariatric Surgery in Italy: Results of Decision-Analytic Modelling. <i>Obesity Facts</i> , 2017, 10, 261-272.	1.6	20
89	COSIMO “ patients with active cancer changing to rivaroxaban for the treatment and prevention of recurrent venous thromboembolism: a non-interventional study. <i>Thrombosis Journal</i> , 2018, 16, 21.	0.9	20
90	Patient Management Strategies and Long-Term Outcomes in Isolated Distal Deep-Vein Thrombosis versus Proximal Deep-Vein Thrombosis: Findings from XALIA. <i>TH Open</i> , 2019, 03, e85-e93.	0.7	20

#	ARTICLE	IF	CITATIONS
91	Systematic literature review on economic implications and pharmacoeconomic issues of psoriatic arthritis. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, S126-31.	0.4	20
92	Cardiac resynchronization therapy: a cost or an investment?. <i>Europace</i> , 2011, 13, ii32-ii38.	0.7	19
93	Compliance, persistence, costs and quality of life in young patients treated with antipsychotic drugs: results from the COMETA study. <i>BMC Psychiatry</i> , 2013, 13, 98.	1.1	19
94	Health economic models in hemophilia A and utility assumptions from a clinician's perspective. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1826-1831.	0.8	19
95	Cost-Effectiveness of New Direct-Acting Antivirals to Prevent Post-Liver Transplant Recurrent Hepatitis. <i>American Journal of Transplantation</i> , 2015, 15, 1817-1826.	2.6	19
96	Management of treatment-naïve chronic hepatitis C genotype 1 patients: a cost-effectiveness analysis of treatment options. <i>Journal of Viral Hepatitis</i> , 2015, 22, 175-183.	1.0	19
97	Direct-acting antivirals combination for elderly patients with chronic hepatitis C: A cost-effectiveness analysis. <i>Liver International</i> , 2017, 37, 982-994.	1.9	19
98	Rivaroxaban for Thromboprophylaxis After Fracture-Related Orthopedic Surgery in Routine Clinical Practice. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2016, 22, 138-146.	0.7	18
99	Subgroup Analysis of Patients with Cancer in XALIA: A Noninterventional Study of Rivaroxaban versus Standard Anticoagulation for VTE. <i>TH Open</i> , 2017, 01, e33-e42.	0.7	18
100	Characteristics, treatment, and outcomes of newly diagnosed atrial fibrillation patients with heart failure: GARFIELD-AF. <i>ESC Heart Failure</i> , 2021, 8, 1139-1149.	1.4	18
101	The pharmacoeconomic impact of amlodipine use on coronary artery disease. <i>Pharmacological Research</i> , 2006, 54, 158-163.	3.1	17
102	Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery. <i>Vascular Health and Risk Management</i> , 2012, 8, 363.	1.0	17
103	Haemophilia prophylaxis: how can we justify the costs?. <i>Haemophilia</i> , 2012, 18, 680-684.	1.0	17
104	Rivaroxaban compared with standard thromboprophylaxis after major orthopaedic surgery: co-medication interactions. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 724-734.	1.1	17
105	XALIA-LEA: An observational study of venous thromboembolism treatment with rivaroxaban and standard anticoagulation in the Asia-Pacific, Eastern Europe, the Middle East, Africa and Latin America. <i>Thrombosis Research</i> , 2019, 176, 125-132.	0.8	17
106	Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry. <i>Indian Heart Journal</i> , 2018, 70, 828-835.	0.2	16
107	Benefits in pain perception, ability function and health-related quality of life in patients with failed back surgery syndrome undergoing spinal cord stimulation in a clinical practice setting. <i>Health and Quality of Life Outcomes</i> , 2018, 16, 68.	1.0	16
108	COVID-19 and Obesity: Is Bariatric Surgery Protective? Retrospective Analysis on 2145 Patients Undergone Bariatric-Metabolic Surgery from High Volume Center in Italy (Lombardy). <i>Obesity Surgery</i> , 2021, 31, 942-948.	1.1	16

#	ARTICLE	IF	CITATIONS
109	Pregnancy-Associated Venous Thromboembolism: Insights from GARFIELD-VTE. <i>TH Open</i> , 2021, 05, e24-e34.	0.7	16
110	Clinical epidemiology of hand eczema in patients accessing dermatological reference centres: results from Italy. <i>British Journal of Dermatology</i> , 2015, 172, 187-195.	1.4	15
111	Patients' and physicians', nurses', and pharmacists' preferences on the characteristics of biologic agents used in the treatment of rheumatic diseases. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 2153-2168.	0.8	15
112	Health related quality of life in chronic liver diseases. <i>Liver International</i> , 2020, 40, 2630-2642.	1.9	15
113	Comparative analysis of the pivotal studies of extended half-life recombinant FVIII products for treatment of haemophilia A. <i>Haemophilia</i> , 2021, 27, e422-e433.	1.0	14
114	Patient Preferences Regarding Anticoagulation Therapy in Patients with Cancer Having a VTE Event - a Discrete Choice Experiment in the Cosimo Study. <i>Blood</i> , 2019, 134, 2159-2159.	0.6	14
115	Modern Treatments of Haemophilia: Review of Cost-Effectiveness Analyses and Future Directions. <i>Pharmacoeconomics</i> , 2018, 36, 263-284.	1.7	13
116	Systematic review: economic evaluations of HCV screening in the direct-acting antivirals era. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1126-1133.	1.9	13
117	KRAS Early Testing: Consensus Initiative and Cost-Effectiveness Evaluation for Metastatic Colorectal Patients in an Italian Setting. <i>PLoS ONE</i> , 2014, 9, e85897.	1.1	12
118	Prior stroke and transient ischemic attack as risk factors for subsequent stroke in atrial fibrillation patients: A report from the GARFIELD-AF registry. <i>International Journal of Stroke</i> , 2020, 15, 308-317.	2.9	12
119	Estimates of the initial impact of the COVID-19 epidemic on overall mortality: evidence from Italy. <i>ERJ Open Research</i> , 2020, 6, 00179-2020.	1.1	12
120	Anticoagulation Treatment in Cancer-Associated Venous Thromboembolism: Assessment of Patient Preferences Using a Discrete Choice Experiment (COSIMO Study). <i>Thrombosis and Haemostasis</i> , 2021, 121, 206-215.	1.8	12
121	Major Diabetes Complications Have an Impact on Total Annual Medical Cost of Type 2 Diabetes. <i>Diabetes Care</i> , 2004, 27, 1841-1842.	4.3	11
122	Amlodipine: a pharmacoeconomic review. <i>Journal of Medical Economics</i> , 2009, 12, 60-68.	1.0	11
123	Long Term Evaluation of the Impact of Autologous Peripheral Blood Stem Cell Transplantation in Multiple Myeloma: A Cost-Effectiveness Analysis. <i>PLoS ONE</i> , 2013, 8, e75047.	1.1	11
124	Stroke prevention, 1-year clinical outcomes and healthcare resource utilization in patients with atrial fibrillation in France: Data from the GARFIELD-AF registry. <i>Archives of Cardiovascular Diseases</i> , 2018, 111, 749-757.	0.7	11
125	Perspectives to mitigate payer uncertainty in health technology assessment of novel oncology drugs. <i>Journal of Market Access & Health Policy</i> , 2019, 7, 1562861.	0.8	11
126	The rationale of pharmacoeconomic analysis in rheumatologic indications. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, S64-71.	0.4	11

#	ARTICLE	IF	CITATIONS
127	Pharmacoeconomic Issues in Psoriatic Arthritis. Journal of rheumatology Supplement, The, 2012, 89, 103-105.	2.2	10
128	Effective but costly: How to tackle difficult trade-offs in evaluating health improving technologies in liver diseases. Hepatology, 2016, 64, 1331-1342.	3.6	10
129	Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian Perspective. Dermatology and Therapy, 2016, 6, 151-167.	1.4	10
130	Sacubitril/valsartan in heart failure with reduced ejection fraction: cost and effectiveness in the Italian context. European Journal of Heart Failure, 2017, 19, 1551-1553.	2.9	10
131	Anticoagulant treatment for venous thromboembolism: A pooled analysis and additional results of the XALIA and XALIA-LEA noninterventional studies. Research and Practice in Thrombosis and Haemostasis, 2021, 5, 426-438.	1.0	10
132	Patient-reported outcomes associated with changing to rivaroxaban for the treatment of cancer-associated venous thromboembolism - The COSIMO study. Thrombosis Research, 2021, 206, 1-4.	0.8	10
133	Moving Towards Accountability for Reasonableness - A Systematic Exploration of the Features of Legitimate Healthcare Coverage Decision-Making Processes Using Rare Diseases and Regenerative Therapies as a Case Study. International Journal of Health Policy and Management, 2019, 8, 424-443.	0.5	10
134	The agenda of the global patient reported outcomes for multiple sclerosis (PROMS) initiative: Progresses and open questions. Multiple Sclerosis and Related Disorders, 2022, 61, 103757.	0.9	10
135	Cost-effectiveness of different diagnostic strategies to assess gastro-oesophageal reflux disease in patients with unexplained chronic persistent cough in Italy. Digestive and Liver Disease, 2006, 38, 452-458.	0.4	9
136	The effects of timing of prophylaxis, type of anesthesia, and use of mechanical methods on outcome in major orthopedic surgery - subgroup analyses from 17,701 patients in the XAMOS study. Vascular Health and Risk Management, 2016, 12, 209.	1.0	9
137	Analysis of patients with deep vein thrombosis switched from standard therapy to rivaroxaban in the non-interventional XALIA study. Thrombosis Research, 2017, 155, 23-27.	0.8	9
138	Thromboembolic event rate in patients exposed to anti-inhibitor coagulant complex: a meta-analysis of 40-year published data. Blood Advances, 2017, 1, 2637-2642.	2.5	9
139	Psoriatic arthritis: Pharmacoeconomic considerations. Current Rheumatology Reports, 2009, 11, 263-269.	2.1	8
140	Severe Acute Respiratory Syndrome Coronavirus 2 Lethality Did not Change Over Time in Two Italian Provinces. Open Forum Infectious Diseases, 2020, 7, ofaa556.	0.4	8
141	Management strategies and clinical outcomes in patients with inferior vena cava thrombosis: Data from GARFIELD-VTE. Journal of Thrombosis and Haemostasis, 2021, , .	1.9	8
142	Antidepressants Drug Use during COVID-19 Waves in the Tuscan General Population: An Interrupted Time-Series Analysis. Journal of Personalized Medicine, 2022, 12, 178.	1.1	8
143	Impact of COVID-19 Lockdown, during the Two Waves, on Drug Use and Emergency Department Access in People with Epilepsy: An Interrupted Time-Series Analysis. International Journal of Environmental Research and Public Health, 2021, 18, 13253.	1.2	8
144	CAPTOPRIL IN THE MANAGEMENT OF PATIENTS AFTER ACUTE MYOCARDIAL INFARCTIONS. A COST EFFECTIVENESS ANALYSIS IN ITALY. Pharmacological Research, 1998, 37, 345-351.	3.1	7

#	ARTICLE	IF	CITATIONS
145	Pharmacoeconomic consequences of amlodipine besylate therapy in patients undergoing PTCA. <i>Pharmacological Research</i> , 2006, 53, 197-201.	3.1	7
146	Healthcare costs associated with hepatocellular carcinoma and the value of care. <i>Hepatology</i> , 2013, 58, 1213-1214.	3.6	7
147	The economic impact of hypercholesterolemia and mixed dyslipidemia: A systematic review of cost of illness studies. <i>PLoS ONE</i> , 2021, 16, e0254631.	1.1	7
148	Cost-minimization analysis of a wearable cardioverter defibrillator in adult patients undergoing <sc>ICD</sc> explant procedures: Clinical and economic implications. <i>Clinical Cardiology</i> , 2021, 44, 1497-1505.	0.7	7
149	Long-term costs and outcomes in psoriatic arthritis patients not responding to conventional therapy treated with tumour necrosis factor inhibitors: the extension of the Psoriatic Arthritis Cost Evaluation (PACE) study. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 68-75.	0.4	7
150	THE PERSPECTIVE OF A PHARMACOECONOMIC STUDY: TARGETING FOR AUDIENCES. <i>Pharmacological Research</i> , 1997, 35, 471-475.	3.1	6
151	Costs and effects of cardiovascular risk reclassification using the ankle-brachial index (ABI) in addition to the Framingham risk scoring in women. <i>Atherosclerosis</i> , 2021, 317, 59-66.	0.4	6
152	Cost-effectiveness analysis of oral fentanyl formulations for breakthrough cancer pain treatment. <i>PLoS ONE</i> , 2017, 12, e0179523.	1.1	6
153	The value of wearable cardioverter defibrillator in adult patients with recent myocardial infarction: Economic and clinical implications from a health technology assessment perspective. <i>International Journal of Cardiology</i> , 2022, 356, 12-18.	0.8	6
154	The burden of renal cell cancer: A retrospective longitudinal study on occurrence, outcomes and cost using an administrative claims database. <i>European Journal of Cancer, Supplement</i> , 2008, 6, 46-51.	2.2	5
155	Patient-Reported Treatment Experience with Oral Rivaroxaban: Results from the Noninterventional XALIA Study of Deep-Vein Thrombosis. <i>TH Open</i> , 2018, 02, e139-e146.	0.7	5
156	Clinical outcome indicators in chronic hepatitis B and C: A primer for value-based medicine in hepatology. <i>Liver International</i> , 2020, 40, 60-73.	1.9	5
157	Estimates of Cancer Mortality Attributable to Carcinogenic Infections in Italy. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 8723.	1.2	5
158	Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis. <i>Clinical Drug Investigation</i> , 2020, 40, 319-326.	1.1	5
159	Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in Patients with Coronary and Peripheral Artery Diseases in Italy. <i>Clinical Drug Investigation</i> , 2021, 41, 459-468.	1.1	5
160	Haemophilia management and treatment: An Italian survey on patients'™, caregivers'™ and clinicians'™ point of view. <i>Haemophilia</i> , 2022, 28, 254-263.	1.0	5
161	Pharmaco-Economic Consequences of Losartan Therapy in Patients Undergoing Diabetic End Stage Renal Disease in EU and USA. <i>Clinical and Experimental Hypertension</i> , 2011, 33, 174-178.	0.5	4
162	The importance of baseline viral load when assessing relative efficacy in treatment-naïve HBeAg-positive chronic hepatitis B: a systematic review and network meta-analysis. <i>Systematic Reviews</i> , 2014, 3, 21.	2.5	4

#	ARTICLE	IF	CITATIONS
163	Peripheral arterial disease in diabetic patients: a long-term population-based study on occurrence, outcomes and cost. <i>Journal of Cardiovascular Surgery</i> , 2018, 59, 572-579.	0.3	4
164	A review of global health technology assessments of non-VKA oral anticoagulants in non-valvular atrial fibrillation. <i>International Journal of Cardiology</i> , 2020, 319, 85-93.	0.8	4
165	The use of individual patient-level data (IPD) to quantify the impact of pretreatment predictors of response to treatment in chronic hepatitis B patients. <i>BMJ Open</i> , 2013, 3, e001309.	0.8	3
166	Optimising the clinical strategy for autoimmune liver diseases: Principles of value-based medicine. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 1415-1422.	1.8	3
167	Healthcare resource use in XALIA: A subgroup analysis of a non-interventional study of rivaroxaban versus standard anticoagulation for deep vein thrombosis. <i>European Journal of Internal Medicine</i> , 2019, 61, 29-33.	1.0	3
168	COVID-19 Outbreak Impact on Anticoagulants Utilization: An Interrupted Time-Series Analysis Using Health Care Administrative Databases. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1115-1118.	1.8	3
169	Meta-Analysis on Incidence of Inhibitors in 1,945 Previously Untreated Patients Treated with Recombinant Factor VIII Products: Is There a Difference?. <i>Blood</i> , 2015, 126, 289-289.	0.6	3
170	Indirect Treatment Comparison of Dabigatran versus Tirofiban as Prophylactic Treatment in Patients with Hemophilia A. <i>Journal of Blood Medicine</i> , 2021, Volume 12, 935-943.	0.7	3
171	Cancer-Associated Thrombotic Events: Patient-Reported Outcomes With Rivaroxaban (COSIMO) – Baseline characteristics and clinical outcomes. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12604.	1.0	3
172	Cost-effectiveness analysis of new drugs for chronic hepatitis C: The importance of updating utility values. <i>Hepatology</i> , 2015, 61, 1096-1097.	3.6	2
173	Rivaroxaban for Thromboprophylaxis After Total Hip or Knee Replacement Surgery: Comparison of Outcomes of the XAMOS and RECORD Studies. <i>Blood</i> , 2012, 120, 500-500.	0.6	2
174	Xalia, a Non-Interventional Study Comparing Rivaroxaban with Standard Anticoagulation for Initial and Long-Term Therapy in Deep Vein Thrombosis. <i>Blood</i> , 2015, 126, 894-894.	0.6	2
175	Subgroup Analysis of Patients with Cancer in Xalia - a Non-Interventional Study of Rivaroxaban in Routine Treatment of Deep Vein Thrombosis. <i>Blood</i> , 2016, 128, 1438-1438.	0.6	2
176	Cost-effectiveness and budget impact analysis of siponimod in the treatment of secondary progressive multiple sclerosis in Italy. <i>PLoS ONE</i> , 2022, 17, e0264123.	1.1	2
177	Multiple Sclerosis Progressive Courses: A Clinical Cohort Long-Term Disability Progression Study. <i>Value in Health</i> , 2022, 25, 1489-1498.	0.1	2
178	Reply to the Letter to the Editor by Hughes in response to the article entitled "Multicentre randomised Phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced NSCLC", published in vol. 41 Issue 1 of the <i>European Journal of Cancer</i> . <i>European Journal of Cancer</i> , 2005, 41, 1656-1657.	1.3	1
179	Oral antiviral therapies are cost-effective vs. no treatment but indirect comparisons should be avoided. <i>Journal of Hepatology</i> , 2009, 51, 1086-1087.	1.8	1
180	Real life studies and good clinical practice – Authors' reply. <i>Lancet Haematology</i> , 2016, 3, e160-e161.	2.2	1

#	ARTICLE	IF	CITATIONS
181	Letter to the editor: Clinical Use, Quality of Life and Cost-Effectiveness of Spinal Cord Stimulation Used to Treat Patients with Failed Back Surgery Syndrome. Asian Spine Journal, 2017, 11, 675-676.	0.8	1
182	Cost-effectiveness of the early arthritis clinic organizational model: the <scp>ELECTRA</scp> study. Arthritis Care and Research, 2022, , .	1.5	1
183	Is Preventive Medical Care Worth the Cost?. Biologicals, 1997, 25, 247-252.	0.5	0
184	The Economic Impact of Long-Term Oxygen Therapy. , 2012, , 221-232.		0
185	Regarding "Exploring patient involvement in decision making for vascular procedures" Journal of Vascular Surgery, 2016, 63, 1668.	0.6	0
186	Drug utilization research and pharmacoeconomics. , 2016, , 425-432.		0
187	Evaluation of cost-effectiveness of early KRAS testing in high-risk recurrence colorectal cancer patients in Italy.. Journal of Clinical Oncology, 2012, 30, e14113-e14113.	0.8	0
188	Editorial to Chuang et al. IJC Heart and Vasculature, 2022, 39, 100963.	0.6	0
189	Title is missing!. , 2020, 15, e0235248.		0
190	Title is missing!. , 2020, 15, e0235248.		0
191	Title is missing!. , 2020, 15, e0235248.		0
192	Title is missing!. , 2020, 15, e0235248.		0
193	Title is missing!. , 2020, 15, e0235248.		0
194	Title is missing!. , 2020, 15, e0235248.		0
195	Title is missing!. , 2020, 15, e0235248.		0
196	Title is missing!. , 2020, 15, e0235248.		0